Identification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry

Clinical and Vaccine Immunology

Volumn 21, Issue 1, 2014, Pages 74-84

  Zhao, Weiwei ^a   Minderman, Hans ^b   Russell, Michael W ^a,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL ANTIGEN; CD103 ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CCR7; CHIMERIC PROTEIN; CHOLERA TOXIN; FLUORESCENT DYE; GLYCOPROTEIN P 15095; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STREPTOCOCCUS MUTANS ANTIGEN AGI; STREPTOCOCCUS MUTANS ANTIGEN AGII; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DENTAL CARIES; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOGENICITY; INTESTINE CELL; LAMINA PROPRIA; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STREPTOCOCCUS MUTANS; TH1 CELL; TH17 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; FEMALE; FLOW CYTOMETRY; GASTRIC LAVAGE; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS MUTANS; VACCINES, SYNTHETIC;

EID: 84892169040     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00452-13     Document Type: Article

References (42)

1. Hajishengallis G, Arce S, Gockel CM, Connell TD, Russell MW. 2005. Immunomodulation with enterotoxins for the generation of secretory immunity or tolerance: applications for oral infections. J. Dent. Res. 84: 1104-1116. http://dx.doi.org/10.1177/154405910508401205.
2. Elson CO, Dertzbaugh MT. 2005. Mucosal adjuvants, p 967-986. In Mestecky J, Bienenstock J, Lamm ME, Mayer L, Strober W, McGhee JR (ed), Mucosal immunology, 3rd ed. Elsevier/Academic Press, San Diego, CA.
3. Connell TD. 2007. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev. Vacc. 6: 821-834. http://dx.doi.org/10. 1586/14760584.6.5.821.
4. Clemens JD, van Loon F, Sack DA, Chakraborty J, Rao MR, Ahmed F, Harris JR, Khan MR, Yunus M, Huda S, Kay BA, Svennerholm AM, Holmgren J. 1991. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163: 1235-1242. http://dx.doi.org/10.1093/infdis/163.6.1235.
5. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. 1989. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramu-cosal tissues. Infect. Immun. 57: 1072-1077. http://dx.doi.org/10.1111/j.1365-2249.2004.02520. x.
6. Russell MW, Wu HY. 1991. Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect. Immun. 59: 4061-4070. http://dx.doi.org/10.1111/j.1365-2567.2005.02246.x.
7. Katz J, Harmon CC, Buckner GP, Richardson GJ, Russell MW, Michalek SM. 1993. Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin. Infect. Immun. 61: 1964-1971.
8. Wu H-Y, Russell MW. 1993. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 61: 314-322.
9. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. 1996. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with abacterial protein antigen and the cholera toxin B subunit. Infect. Immun. 64: 1272-1283.
10. Hajishengallis G, Hollingshead SK, Koga T, Russell MW. 1995. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J. Immunol. 154: 4322-4332.
11. Hajishengallis G, Russell MW, Michalek SM. 1998. Comparison of an adherence domain and a structural domain of Streptococcus mutans antigen I/II in protective immunity against dental caries in rats after intranasal immunization. Infect. Immun. 66: 1740-1743.
12. Sun JB, Holmgren J, Czerkinsky C. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 91: 10795-10799. http://dx.doi.org/10.1073/pnas.91.23.10795.
13. Lycke N. 2005. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol. Lett. 97: 193-198. http://dx.doi.org/10.1016/j.imlet.2004.12.008.
14. Toida N, Hajishengallis G, Wu H-Y, Russell MW. 1997. Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T helper cell responses in gut-associated lymphoid tissues. Infect. Immun. 65: 909-915.
15. Gockel CM, Russell MW. 2005. Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology 116: 477-486. http://dx.doi.org/10.1111/j.1365-2567.2005. 02246.x.
16. Zhao W, Zhao Z, Russell MW. 2011. Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins. Mol. Oral Microbiol. 26: 200-209. http://dx.doi.org/10.1111/j. 2041-1014.2011.00608.x.
17. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl JP, Ricciardi-Castagnoli P. 2001. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2: 361-367. http://dx.doi.org/10.1038/86373.
18. Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM, Foschi D, Caprioli F, Viale G, Rescigno M. 2009. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58: 1481-1489. http://dx.doi.org/10.1136/gut.2008.175166.
19. Rescigno M. 2011. Dendritic cells in oral tolerance in the gut. Cell. Microbiol. 13: 1312-1318. http://dx.doi.org/10.1111/j.1462-5822.2011.01626.x.
20. Cyster JG. 1999. Chemokines and cell migration in secondary lymphoid organs. Science 286: 2098-2102. http://dx.doi.org/10.1126/science.286.5447.2098.
21. Lee CH, Masso-Welch P, Hajishengallis G, Connell TD. 2011. TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin. J. Leukoc. Biol. 90: 911-921. http://dx.doi.org/10.1189/jlb.0511236.
22. Anosova NG, Chabot S, Shreedhar V, Borawski JA, Dickinson BL, Neutra MR. 2008. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucos. Immunol. 1: 59-67. http://dx.doi.org/10.1038/mi.2007.7.
23. Gustafsson T, Hua Y-J, Dahlgren M, Livingston M, Johansson-Lindbom B, Yrlid U. 2013. Direct interaction between cholera toxin and dendritic cells is required for oral adjuvant activity. Eur. J. Immunol. 43: 1779-1788. http://dx.doi.org/10.1002/eji.201242867.
24. Gloudemans AK, Plantinga M, Guilliams M, Willart MA, Ozir-Fazalalikhan A, van der Ham A, Boon L, Harris NL, Hammad H, Hoogsteden HC, Yazdanbakhsh M, Hendriks RW, Lambrecht BN, Smits HH. 2013. The mucosal adjuvant cholera toxin B instructs non-mucosal dendritic cells to promote IgA production via retinoic acid and TGF-β. PLoS One 8:e59822. http://dx.doi.org/10.1371/journal.pone. 0059822.
25. + dendritic cells. Eur. J. Immunol. 40: 1877-1883. http://dx.doi.org/10.1002/eji.200939957.
26. + dendritic cells in both tolerogenic and immunogenic T-cell responses. Mucosal Immunol. 5: 150-160. http://dx.doi.org/10.1038/mi.2011.61.
27. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. 2001. The immunological synapse. Annu. Rev. Immunol. 19: 375-396. http://dx.doi.org/10.1146/annurev.immunol.19.1.375.
28. + T helper cells. Cell 126: 1121-1133. http://dx.doi.org/10.1016/j.cell.2006.07.035.
29. Hajishengallis G, Michalek SM, Russell MW. 1996. Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Infect. Immun. 64: 665-667.
30. Hirota K, Turner J-E, Villa M, Duarte JH, Demengeot J, Steinmetz OM, Stockinger B. 2013. Plasticity of TH17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 14: 372-379. http://dx.doi.org/10.1038/ni.2552.
31. Jaffar Z, Ferrini ME, Herritt LA, Roberts K. 2009. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J. Immunol. 182: 4507-4511. http://dx.doi.org/10.4049/jimmunol.0900237.
32. Wilson AD, Robinson A, Irons L, Stokes CR. 1993. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 11: 113-118. http://dx.doi.org/10.1016/ 0264-410X(93)90004-H.
33. Lycke N, Tsuji T, Holmgren J. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22: 2277-2281. http://dx.doi.org/10.1002/eji.1830220915.
34. Yamamoto M, Kiyono H, Yamamoto S, Batanero E, Kweon MN, Otake S, Azuma M, Takeda Y, McGhee JR. 1999. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162: 7015-7021.
35. Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KHG. 2000. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the non-toxic AB complex and the enzyme activity. J. Immunol. 165: 5750-5759.
36. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR. 1996. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl. Acad. Sci. U. S. A. 93: 226-230. http://dx.doi.org/10.1073/ pnas.93.1.226.
37. Guidry JJ, Cárdenas L, Cheng E, Clements JD. 1997. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect. Immun. 65: 4943-4950.
38. Martin M, Hajishengallis G, Metzger DJ, Michalek SM, Connell TD, Russell MW.2001. Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of T cells. Infect. Immun. 69: 252-261. http://dx.doi.org/10.1128/IAI.69.1.252-261. 2001.
39. Price GA, Masri HP, Hollander AM, Russell MW, Cornelissen CN. 2007. Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. Vaccine 25: 7247-7260. http://dx.doi.org/10.1016/ j.vaccine.2007.07.038.
40. Price GA, Holmes RK. 2012. Evaluation of TcpF-A2-CTB chimera and evidence ofadditive protective efficacyofimmunizing with TcpF and CTB in the suckling mouse model of cholera. PLoS One 7:e42434. http://dx.doi.org/10.1371/journal. pone.0042434.
41. Singh SR, Hulett K, Pillai SR, Dennis VA, Oh MK, Scissum-Gunn K. 2006. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 24: 1213-1224. http://dx.doi.org/10.1016/j.vaccine.2005.08.097.
42. Sheoran AS, Artiushin S, Timoney JF. 2002. Nasal mucosal immunogenicity for the horse of a SeM peptide of Streptococcus equi genetically coupled to cholera toxin. Vaccine 20: 1653-1659. http://dx.doi.org/10.1016/S0264-410X(01) 00488-1.